News & Events
Published On: 2/2/2021
Target RWE Shares Weight Loss Data From Ongoing NASH Study
Real-world study shows only 32% of overweight or obese adults with NAFLD in the U.S. achieved 5% or more weight reduction
DURHAM, N.C., Feb. 2, 2021 /PRNewswire/ -- Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, shared the latest data from the ongoing TARGET-NASH observational study, published in Clinical Gastroenterology & Hepatology (https://doi.org/10.1016/j.cgh.2021.01.023).
The nonalcoholic steatohepatitis (NASH) study, Weight Loss and Weight Regain in Usual Clinical Practice: Results from the TARGET-NASH Observational Cohort, analyzed 2,019 patients enrolled in the TARGET-NASH cohort in the United States over a median follow-up of 39 months. The baseline characteristics included one third of patients classified as obesity class 2/3, 38.6% of patients had diabetes, and approximately 50% had documentation of lifestyle modifications or diet recommendations.
Over a median follow-up of 39 months, the study found the following results:
- 32% of patients had weight reduction of 5% or more;
- Median time to initial weight loss was shorter in patients who were obesity class 2/3; and
- Only 25% of patients maintained 5% or more weight loss.
"We know that obesity and metabolic syndrome are major risk factors for the development of nonalcoholic fatty liver disease (NAFLD), and its more severe form, NASH. Thus, lifestyle modifications such as weight reduction are a critical step in the treatment of the disease," said Miguel Malespin, MD, Transplant Hepatology Specialist, Tampa General Hospital, and lead author on the manuscript. "The results of weight loss and weight gain from the TARGET-NASH cohort can help inform future studies of management of NAFLD."
"Our analyses found that among those with initial weight loss, 21% regained weight back to baseline during follow-up, and 59% of those patients did so within the first year of weight loss," said Anna Lok, MD, Professor of Medicine, University of Michigan, and senior author. "These data have implications for identifying patient populations who are more or less likely to lose weight in the absence of pharmacological interventions and provide important background information for the interpretation of clinical trial results."
TARGET-NASH is a longitudinal study of adults and pediatric participants with NAFLD and/or NASH in usual clinical practice. Target RWE's NASH sites include 65 community and academic centers in the U.S. and Europe that have enrolled more than 5,700 participants to date. Three years of retrospective data is obtained at time of enrollment and patients are then followed prospectively for a minimum of 5 years, including patient-reported outcome measures and biospecimen samples.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
07/22/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients
06/15/2021TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
05/25/2021Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required Readmission